A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

CORI Surgical System Launches

The Next-Generation Handheld Robotics Platform

What To Know

  • The CORI Surgical System has received 510K clearance from the United States Food and Drug Administration (FDA) and is available for sale in the US for both total and unicompartmental knee arthroplasty applications.
  • CORI includes new camera technology which is over four times faster, offers more efficient cutting technology with twice the cutting volume, and aims to result in a faster robotic surgical procedure compared to the NAVIO™ Surgical System.

CORI Surgical System has been launched by Smith+Nephew.  The launch of its Real Intelligence brand of enabling technology solutions, as well as its new-generation handheld robotics platform, the CORI Surgical System.

CORI Surgical System: Smith+Nephew states Real Intelligence will address clinical challenges through the continuum of care including patient engagement, pre-operative planning, digital and robotic surgery, post-operative assessment and outcomes measurement. Each solution in the Real Intelligence digital ecosystem informs the next phase of treatment, and over time will allow healthcare providers to use outcomes data to better inform patient-specific treatments.

The new CORI surgical platform is now available for both unicompartmental knee arthroplasty and total knee arthroplasty. It small and portable, making it ideal for ambulatory surgery centers (ASCs) and outpatient surgery. CORI includes new camera technology which is over four times faster, offers more efficient cutting technology with twice the cutting volume, and aims to result in a faster robotic surgical procedure compared to the NAVIO™ Surgical System.1 CORI is surgeon-controlled handheld robotics, and its modular design will enable it to be scaled across the orthopedic service line. Smith+Nephew will continue to introduce new applications for this robotics platform.

“The CORI Surgical System is truly next-generation robotics. Its efficient handheld form factor is ideal for surgery centers, which is where the market is moving, and it just erases away bone with the new bone milling technique,” said Dr. Jimmy Chow, Orthopaedic Surgeon for Hip and Knee, Orthopedic Institute of the West. “The smart, intuitive software helps place and size the implant as well as balance gaps based on patient-specific anatomy and disease state.”

“The Real Intelligence brand is a statement of how Smith+Nephew thinks, innovates, and reimagines surgery,” said Skip Kiil, President of Orthopaedics for Smith+Nephew. “The introduction of the CORI Surgical System’s handheld robotics, patient engagement tools, and outcomes measurement are the very first steps in a long-term strategy to advance orthopedics using technology.”

The CORI Surgical System has received 510K clearance from the United States Food and Drug Administration (FDA) and is available for sale in the US for both total and unicompartmental knee arthroplasty applications.

Medical Device News Magazinehttp://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.